Benefits
UC remission maintenance equivalent to mesalazine (Kruis 2004 PIVOTAL)
Kruis W et al. 2004 (PMC1774300, Gut) — randomized double-blind double-dummy trial. 327 patients with ulcerative colitis assigned to either MUTAFLOR® 200 mg once daily (n=162) or mesalazine 500 mg three times daily (n=165) for 12 MONTHS. Clinical, endoscopic (Rachmilewitz), histological assessment. RESULTS: EcN equivalent to mesalazine in maintaining UC remission. Foundational pivotal evidence — first-line probiotic with EQUIVALENCE to standard pharmaceutical UC therapy. ECCO guideline-recognized.
First UC remission maintenance trial (Kruis 1997)
Kruis 1997 — first 120-patient randomized double-blind double-dummy trial in Germany, Czech Republic, Austria. UC patients in remission (CAI<4, no acute inflammation). 500 mg mesalazine TID + EcN placebo or 200 mg/d EcN + mesalazine placebo for 12 weeks. Foundational original trial establishing EcN as UC remission maintenance therapy. Three subsequent randomized double-blind studies confirmed equivalence to mesalazine.
Active distal UC dose-dependent rectal improvement (Matthes 2010)
Matthes H et al. 2010 (BMC Complement Altern Med 10:13) — clinical trial in active distal UC. 57 patients received 10/20/40 mL of EcN (10^8 CFU/mL) rectally for max 8 weeks. RESULTS: REMISSION (DAI≤2) reached in placebo 18.2%, 10-mL EcN 27.3%, 20-mL EcN 44.4%, 40-mL EcN 52.9%. DOSE-DEPENDENT improvement of clinical, endoscopic, histological findings of active mild-to-moderate distal UC. Important active disease (not just maintenance) evidence.
Additive effect to 5-ASA in mild-to-moderate UC (NCT04969679 2022)
NCT04969679 (Park SK et al. 2022, Korean J Intern Med 37(5):949-957) — multicenter double-blind randomized placebo-controlled study at Kangbuk Samsung Hospital, Korea. 133 patients with mild-to-moderate UC (Mayo score 3-9) on 5-ASA. EcN (Mutaflor®) or placebo once daily for 8 weeks. ADDITIVE effect of EcN to standard 5-ASA mesalazine therapy investigated. Recent evidence supporting ADD-ON therapy use beyond monotherapy.
Crohn's disease remission maintenance (Malchow 1997)
Malchow HA 1997 (J Clin Gastroenterol 25(4):653-658) — Crohn's disease and E. coli. New approach in therapy to maintain remission of colonic Crohn's disease. EcN evaluated in CD remission maintenance population. Important emerging Crohn's-specific evidence — distinct indication from UC.
Diarrhea + uncomplicated diverticular disease (additional indications)
Additional clinical applications: ACUTE DIARRHEA, UNCOMPLICATED DIVERTICULAR DISEASE, irritable bowel syndrome subgroups (Kruis IBS subgroup analysis). Mechanism: gut microbiota colonization + competitive exclusion of pathogens + mucosal immune modulation. Multi-indication evidence base.
ECCO guideline recognition (regulatory milestone)
ECCO (European Crohn's & Colitis Organization) Guideline RECOGNIZED E. coli strain Nissle 1917 as EVIDENCE-BASED MEDICINAL SUBSTANCE belonging to PROBIOTICS group for REMISSION MAINTENANCE of ulcerative colitis. EQUIVALENCE of Mutaflor® and mesalazine determined. Important regulatory/professional society recognition — RARE among probiotic supplements.
Mechanism of action
Gut microbiota colonization (UC mechanism)
EcN colonizes gut microbiota — competes with pathogens + supports commensal flora. Mechanism: niche occupation in dysbiotic gut. Key for UC remission maintenance via gut microbiota normalization.
Outer membrane vesicles (OMV) immunomodulation
EcN secretes OUTER MEMBRANE VESICLES (OMVs) carrying bioactive molecules. Mechanism: OMVs interact with intestinal epithelial cells + immune cells modulating mucosal immunity. PMC7271297 characterized intestinal effect of EcN + OMVs.
Tight junction integrity enhancement
EcN supports intestinal epithelial tight junction integrity — important in IBD where barrier function is compromised. Mechanism: claudin/occludin/zonula occludens regulation supporting barrier function.
Mucin production stimulation
Stimulates mucin production by goblet cells supporting mucus layer protection. Mechanism for mucosal protection in IBD where mucus barrier is reduced.
Anti-inflammatory cytokine modulation
Reduces pro-inflammatory cytokines (TNF-α, IL-6, IL-8) + promotes anti-inflammatory cytokines (IL-10). Mechanism for IBD anti-inflammatory effects.
Colicin/microcin antimicrobial production
EcN produces COLICINS + MICROCINS — antimicrobial peptides active against pathogenic E. coli + other Enterobacteriaceae. Mechanism: competitive exclusion of pathogenic bacteria via direct antimicrobial activity.
Iron-uptake siderophores (competitive exclusion)
EcN produces iron-uptake siderophores giving it competitive advantage in iron-limited gut environment. Mechanism: outcompetes pathogenic Enterobacteriaceae for iron.
Clinical trials
Randomized double-blind double-dummy trial (Kruis W et al. 2004, PMC1774300, Gut). Multi-center: Germany, Czech Republic, Austria.
327 patients with ulcerative colitis. MUTAFLOR® 200 mg once daily (n=162) vs MESALAZINE 500 mg three times daily (n=165) for 12 MONTHS. Clinical activity index, endoscopic activity, histology assessed.
EcN EQUIVALENT to mesalazine in maintaining UC remission over 12 months. Foundational pivotal evidence. ECCO guideline-recognized — first-line probiotic with documented equivalence to standard pharmaceutical UC therapy. Industry-related context (Ardeypharm).
Clinical trial (Matthes H et al. 2010, BMC Complement Altern Med 10:13).
57 patients with ACTIVE DISTAL UC (DAI 4-9, mild-to-moderate). 10/20/40 mL of EcN (10^8 CFU/mL) rectally for max 8 weeks vs placebo.
DOSE-DEPENDENT improvement in clinical, endoscopic, histological findings of active mild-to-moderate distal UC. REMISSION (DAI≤2): placebo 18.2%, 10-mL EcN 27.3%, 20-mL EcN 44.4%, 40-mL EcN 52.9%. Important active disease (not just maintenance) evidence — distinct indication.
Multicenter double-blind randomized placebo-controlled study (Park SK, Kang SB, Kim SS et al. 2022, Korean J Intern Med 37(5):949-957). NCT04969679. Sponsor: Kangbuk Samsung Hospital.
133 patients with mild-to-moderate UC (Mayo score 3-9) on 5-ASA. Mean age 46 years. EcN or placebo once daily for 8 weeks. IBDQ scores + clinical remission + response rate compared.
Additive effect of EcN on 5-ASA therapy investigated in mild-to-moderate UC. Recent evidence supporting EcN as ADD-ON therapy beyond monotherapy. Important cohort: Korean population — geographic generalizability evidence beyond European trials. No significant differences in Escherichia/Shigella abundance even in clinical responders.
About this ingredient
ESCHERICHIA COLI NISSLE 1917 (EcN) is a NON-PATHOGENIC E. coli strain with serotype O6:K5:H1 — isolated by Prof. ALFRED NISSLE in FREIBURG GERMANY in 1917 from intestinal microflora of a young soldier who DID NOT develop infectious diarrhea when stationed during WWI in Southeastern Europe (Dobrudja/Balkan peninsula) endemic for Shigella at that time. Distinguishing historical origin: empirical resistance phenotype. Prof. Nissle developed probiotic drug MUTAFLOR® and introduced it 1917. Commercialized by ARDEYPHARM GmbH (Herdecke, Germany) — 100 mg enteric-coated capsule contains 2.5-25×10^9 viable bacteria. PIVOTAL CLINICAL EVIDENCE: KRUIS 2004 PMC1774300 (Gut) PIVOTAL randomized double-blind double-dummy trial in 327 UC patients comparing MUTAFLOR® 200 mg/day vs mesalazine 500 mg TID for 12 MONTHS — EcN EQUIVALENT to mesalazine in maintaining UC remission. KRUIS 1997 (Aliment Pharmacol Ther 11(5):853-858) original 120-patient trial in Germany/Czech Republic/Austria. MATTHES 2010 (BMC Complement Altern Med 10:13) — active distal UC rectal dose-ranging trial showing DOSE-DEPENDENT improvement (placebo 18.2%, 10-mL 27.3%, 20-mL 44.4%, 40-mL 52.9% remission rates). PARK 2022 (Korean J Intern Med 37(5):949-957) NCT04969679 — additive effect of EcN to 5-ASA in mild-to-moderate UC 8-week multi-center Korean RCT. MALCHOW 1997 (J Clin Gastroenterol 25(4):653-658) — Crohn's disease remission maintenance evidence. KRUIS IBS subgroup analysis — IBS subgroup applications. Multiple meta-analyses + systematic reviews. PMC7271297 characterization of EcN intestinal effects + outer membrane vesicles (OMV). REGULATORY MILESTONE: ECCO (European Crohn's & Colitis Organization) Guideline RECOGNIZED EcN as EVIDENCE-BASED MEDICINAL SUBSTANCE belonging to PROBIOTICS group for REMISSION MAINTENANCE of ulcerative colitis — RARE professional society recognition among probiotics.
MECHANISMS: GUT MICROBIOTA COLONIZATION (UC mechanism — niche occupation in dysbiotic gut); OUTER MEMBRANE VESICLES (OMV) immunomodulation (PMC7271297 mechanism); TIGHT JUNCTION INTEGRITY enhancement; MUCIN production stimulation; ANTI-INFLAMMATORY cytokine modulation (TNF-α, IL-6, IL-8 reduction; IL-10 promotion); COLICIN/MICROCIN antimicrobial peptide production (against pathogenic E. coli + Enterobacteriaceae); IRON-UPTAKE SIDEROPHORES (competitive exclusion of pathogenic Enterobacteriaceae). EVIDENCE: 4/5 reflects: (1) KRUIS 2004 PIVOTAL 12-month equivalence-to-mesalazine RCT, (2) KRUIS 1997 + 3 subsequent randomized double-blind UC maintenance trials all confirming equivalence, (3) MATTHES 2010 dose-ranging active distal UC RCT, (4) NCT04969679 Park 2022 recent additive 5-ASA Korean RCT — geographic generalizability + add-on therapy evidence, (5) MALCHOW 1997 Crohn's disease evidence (broader IBD applications), (6) ECCO GUIDELINE RECOGNITION — rare professional society endorsement, (7) MULTIPLE meta-analyses + systematic reviews, (8) WELL-CHARACTERIZED multi-mechanism action (microbiota + tight junction + mucin + cytokine + colicin), (9) historical 100+ year clinical use record + WHO pre-WWII era origin, (10) industry-sponsored evidence (Ardeypharm) — important context but methodology rigorous + multi-investigator + multi-country, (11) higher-evidence than typical Lactobacillus/Bifidobacterium probiotic due to UC remission EQUIVALENCE to pharmaceutical mesalazine + ECCO guideline recognition. SAFETY: Excellent — extensive 12-month clinical trial data. Best positioned as: (a) ULCERATIVE COLITIS REMISSION MAINTENANCE adjunct or alternative to mesalazine (Kruis 2004 PIVOTAL evidence + ECCO guideline), (b) ACTIVE DISTAL UC adjunct (Matthes 2010 dose-dependent rectal evidence), (c) 5-ASA ADDITIVE THERAPY in mild-to-moderate UC (Park 2022 NCT04969679 evidence), (d) CROHN'S DISEASE remission maintenance (Malchow 1997 evidence), (e) IBS SUBGROUPS (Kruis IBS subgroup evidence), (f) UNCOMPLICATED DIVERTICULAR DISEASE adjunct, (g) ACUTE DIARRHEA, (h) MUTAFLOR® branded preparation preferable for clinical evidence-matched formulation, (i) ANTIBIOTIC USERS: take 2-3 hours apart, (j) IMMUNOCOMPROMISED: caution (live bacteria), (k) PREGNANCY: limited data; consult physician, (l) higher-evidence than typical probiotic supplement due to ECCO guideline + 12-month equivalence-to-pharmaceutical RCT + 100+ year clinical history. Honest framing: EcN (Mutaflor®) is one of the BEST-EVIDENCED probiotics in CLINICAL MEDICINE — Kruis 2004 12-month equivalence-to-mesalazine RCT + ECCO guideline recognition is genuinely exceptional evidence base for a probiotic. Multiple confirmatory trials + Crohn's disease evidence + active UC dose-ranging + recent Park 2022 NCT04969679 add-on evidence support multi-context applications. The 100+ year clinical history including WWII-era empirical origin is genuinely distinctive. ECCO guideline recognition as 'evidence-based medicinal substance' is rare among probiotics. Industry sponsorship (Ardeypharm) warrants caveat but methodology consistent across multi-country investigators. Critical practical considerations: REFRIGERATION REQUIRED (live bacteria viability), TAKE WITH COOL WATER (heat sensitivity), 2-3 HOUR SEPARATION from antibiotics. Reasonable UC remission maintenance + IBD adjunct based on rigorous evidence — particularly compelling for those wanting probiotic alternative or adjunct to mesalazine, or those with mesalazine intolerance/contraindications.